We are live on ! Find out more
COEPW

Coeptis Therapeutics Warrants

Delisted

COEPW was delisted on the 24th of April, 2026.

11 hedge funds and large institutions have $4.63K invested in Coeptis Therapeutics Warrants in 2025 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 1111 (0)

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

69% less capital invested

Capital invested by funds: $14.9K → $4.63K (-$10.3K)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2

Holders
11
Holders Change
Holders Change %
0%
% of All Funds
0.13%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
2
Increased
Reduced
2
Closed
2
Calls
Puts
Net Calls
Net Calls Change

COEPW Hedge Fund Activity: Q4 2025 in Review

11 of the 8,228 institutional investors tracked by Wall St. Rank reported a position in Coeptis Therapeutics Warrants (COEPW) for Q4 2025, worth a combined $4.63K — down 69% from $14.9K a quarter earlier.

Fund positioning in COEPW was balanced in Q4 2025: 2 funds opened new positions, 2 closed out, 0 added to existing stakes and 2 trimmed.

The largest buyer was Virtu Financial, opening a new position worth an estimated $403. The largest seller was Meteora Capital, exiting entirely with an estimated $3.02K sold.

  • 11 institutional investors held Coeptis Therapeutics Warrants (COEPW) as of Q4 2025, unchanged from Q3 2025.
  • Funds reported $4.63K of Coeptis Therapeutics Warrants stock for Q4 2025, down 69% quarter-over-quarter.
  • 2 funds opened new Coeptis Therapeutics Warrants positions in Q4 2025 and 2 closed out, a net change of 0 holders.
  • The largest Coeptis Therapeutics Warrants buyer in Q4 2025 was Virtu Financial, an estimated $403 added.
  • The largest Coeptis Therapeutics Warrants seller in Q4 2025 was Meteora Capital, an estimated $3.02K sold.

Based on aggregated 13F filings for Q4 2025.